Intercure Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Interim Financial Results for the First Half of 2026 | 15 Oct 2026 |
| Annual General Meeting of Shareholders | 30 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Annual Revenue (NIS) Annually270MTarget: Sustained double-digit growth
Adjusted EBITDA (NIS) Quarterly47MTarget: Maintain positive trajectory
Operating Cash Flow (NIS) Annually17MTarget: Positive cash generation
Watch Items
- Nasdaq Minimum Bid Price Requirement ComplianceTrigger: Stock price consistently below $1.00Action: Monitor share price performance and evaluate potential reverse stock split or other corrective actions to maintain Nasdaq listing.
- War Damage Compensation ClaimsTrigger: Receipt of final compensation from Israeli authoritiesAction: Track progress of the remaining NIS 169 million claim out of the total NIS 251 million submitted for the Nir Oz facility.
- German Medical Cannabis Market ExpansionTrigger: Product launches and sales volume in GermanyAction: Assess performance of the newly appointed German management team and the commercial reception of new GMP SKU rollouts.
Research as of 19 Jun 2026